Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

In the domain of mass production, the legacy theme of general health and science information has historically served as a foundational resource for public awareness, offering broad insights into wellness and medical conditions without delving into specific product-related risks. This heritage established a baseline understanding of health topics, often focusing on prevention and general risk factors. As we pivot toward a more targeted occupational exposure concern, the transition requires a shift from this broad educational context to a focused examination of how specific substances encountered in manufacturing environments may pose unique health challenges. The bridge concept here involves moving from general health literacy to a precise inquiry into the relationship between a widely prescribed medication, Fosamax, and a serious condition known as osteonecrosis of the jaw. This pivot acknowledges that while general health information serves as a valuable starting point, the nuances of occupational or pharmaceutical exposure demand a more granular analysis. The concern now centers on whether the use of Fosamax, particularly in populations with prolonged exposure, correlates with an elevated risk of jawbone deterioration. This transition reframes the discussion from passive health education to active risk assessment, emphasizing the need for careful scrutiny of exposure pathways and their potential consequences in both clinical and occupational settings.

Understanding Fosamax and Its Mechanism

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. Clinical presentation and diagnosis of ONJ typically involve delayed healing after dental procedures, such as tooth extraction or dental implants, often accompanied by local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition can also occur spontaneously, without an identifiable trigger (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the jawbone showing areas of necrotic bone that fail to heal over weeks to months. Multiscale characterization of jawbone tissue has provided insights into its unique responses to bone-related complications, including bisphosphonate-related ONJ, highlighting the jaw's susceptibility to such adverse effects (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. While this effect is beneficial for osteoporosis, it can impair the jawbone's ability to remodel and repair microdamage, particularly after invasive dental procedures. The reduced blood supply and altered bone metabolism in the jaw may contribute to necrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Labeling

Regarding the adequacy of warnings, the prescribing information for Fosamax explicitly includes a section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for osteoporosis treatment, noting that the optimal duration has not been determined and that for low-risk patients, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of clarity may affect risk communication.

Causation Considerations for Affected Patients

Causation considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing Fosamax, but a subset may have recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, the timeline between exposure and documented harm can be influenced by factors such as dental procedures, concomitant medications, and overall health status. The risk of ONJ may increase with duration of bisphosphonate use, and patients with longer exposure are at higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For those requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the decision to discontinue should be made on a case-by-case basis, weighing the benefits of osteoporosis treatment against the potential for ONJ.

Summary of Evidence

In summary, Fosamax is associated with a risk of osteonecrosis of the jaw, as documented in its prescribing information. The condition is rare but serious, with known risk factors including dental procedures and longer exposure. Warnings are provided in the label, but the optimal duration of use remains undefined, which may complicate risk assessment for patients. Causation requires evidence of exposure, temporal relationship, and exclusion of other causes, with the timeline varying from days to months after starting the drug.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

ONJ is a condition of exposed, non-healing bone in the jaw, often after dental procedures or spontaneously. Diagnosis is based on clinical exam and imaging showing necrotic bone that fails to heal over weeks to months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).